TNFSF10 and neoplasm: Strikingly, 16-h erlotinib markedly increased tumor lysis by NK cells (Figure 3c) or TRAIL (Figure 3d) in PC9 and HCC827 cells, whereas 72-h pre-treatment proved detrimental in both PC9 and HCC827 cells.